Product Data Sheet

Pacific Blue™ anti-human CD45

Catalog # / Size: $2120105 / 25 \mu g$

2120110 / 100 μg

2120145 / 100 tests

Clone: HI30

Isotype: Mouse IgG1, κ

Reactivity: Human

Preparation: The antibody was purified by affinity

chromatography, and conjugated with Pacific Blue™ under optimal conditions. The solution is free of unconjugated

Pacific Blue™.

Formulation: test size: Phosphate-buffered solution,

pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA). microg size: Phosphate-buffered solution, pH 7.2, containing 0.09%


sodium azide.

Workshop Number: IV N816

Concentration:

test size: lot-specific; microg sizes: 0.5

mg/ml



Human peripheral blood lymphocytes stained with HI30 Pacific Blue™

Applications:

Applications: Flow Cytometry

Recommended Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis.

For test size, the suggested use of this reagent for immunofluorescent

staining is 5 microL per 10⁶ cells in 100 microL volume.

For microg sizes, the suggested use of this reagent for immunofluorescent

staining is ≤ 0.5 microg per 10^6 cells in 100 microL volume.

It is recommended that the reagent be titrated for optimal performance for each

application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.

Application Notes:

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections⁹, inhibition of CD45 functions4, immunofluorescence¹¹. and Western blotting3.

It was found that the HI30 clone and the 2D1 clone can cross block each other's

binding.

Application References:

- 1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- 2. Kishihara K, et al. 1993. Cell 74:143.
- 3. Esser M, et al. 2001. J. Virol. 75:6173. (WB)
- 4. Yamada T, et al. 2002. J. Biol. Chem. 277:28830.
- 5. Nagano M, et al. 2007. Blood 110:151.

- 6. Jiang Q, et al. 2008. Blood 112:2858. PubMed
- 7. Morozov A, et al. 2010. Clin Cancer Res. 16:5630. PubMed
- 8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 9. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
- 10. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
- 11. Rees LE, et al. 2003. Clin. Exp. Immunol. 134:497. (IF)
- 12. Lee J, et al. 2015. J Exp Med. 212:385. PubMed
- 13. Breton G, et al. 2015. J Exp Med. 212:401. PubMed
- 14. Marquardt N, et al. 2015. J Immunol. 6:2467. PubMed

Description:

CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

Antigen References:

- 1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
- **References:** 2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.